GlobeNewswire Inc | Aug 19, 2020 04:30AM EDT

August 19, 2020

Leverkusen, Germany, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the Company), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2020 on Wednesday, August 26, 2020.

Conference calls for shareholders and interested investors will be held on Thursday, August 27, 2020, at the following times:

In German, August 27, 2020 at 10:00 am CEST (4:00 am EST)Dial-in number Germany: +49 69201744220Conference code: 43177738#

In English, August 27, 2020 at 2:00 pm CEST (8:00 am EST)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference code: 41610190#

Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.

-End-

For enquiries, please contact:

Biofrontera AG +49 (0) 214 87 63 2 0

Thomas Schaffer, Chief Financial Officer ir@biofrontera.comIR UK: Seton Services

Toni Vallen +44 (0) 207 229 0805

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The companys lead product is the combination of Ameluz, a topical prescription drug, and medical device BF-RhodoLED for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos, which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lbbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.